Xspray-logo-white
  • Home
  • About us
    • Business model
    • Our history – a timeline
    • Board of Directors & Board committees
    • Management
  • Technology
  • Pipeline
  • Media
  • Contact
  • Investors
  • en en
    • sv sv
  • Investors
    • Share information
      • Ownership structure
    • Financial calendar & Events
    • Financial reports
      • ESEF report
    • Prospectus
    • Press releases
    • Corporate governance
      • Corporate Structure
      • General meetings
      • Corporate Governance Reports
      • Nomination committee
      • Board of Directors & Board committees
      • Management
      • Accounting principles
      • Internal control & Risk management
      • Auditor
      • Articles of association
      • Remuneration
    • Rights Issue 2025

Press releases

All press releases Regulatory

Regulatory press release 2021-02-25

Xspray Pharma publishes Interim report Q4, January – December 2020

Regulatory press release 2021-02-17

Nomination Committee proposes Anders Ekblom as new Chairman of the Board in Xspray Pharma

Regulatory press release 2021-01-29

Number of shares and votes in Xspray Pharma

Regulatory press release 2021-01-26

Warrant holders exercise all warrants within the framework of the incentive program

Regulatory press release 2021-01-22

Xspray Pharmas study with modified formulation of HyNap-Dasa has now started

Regulatory press release 2021-01-14

Xspray Pharma announces results from additional bioequivalence study and provides update regarding upcoming regulatory applications for ANDA and 505(b)(2)

Press release 2020-12-30

Xspray Pharma reports positive results from a study with dasatinib during omeprazole treatment

Regulatory press release 2020-12-29

Xspray Pharma’s HyNap-Nilo receives FDA Orphan Drug Designation for the treatment of Chronic Myeloid Leukemia

Press release 2020-12-17

Xspray Pharma moves up to Nasdaq Stockholm’s Mid Cap-segment

Regulatory press release 2020-12-11

Xspray Pharma has decided to await the result of two ongoing clinical studies before submitting its ANDA application

Show more

IR contact

Jacob Nyberg, IRO

+46 (0)70 767 08 83

info@xspray.com

Subscribe

  • Submit to our press releases and get an email every time we publish a press release or report on our website.
  • When clicked on Send I agree that my personal information will be saved. Read more
  • This field is for validation purposes and should be left unchanged.
Xspray-logo-white

Xspray Pharma AB Scheeles väg 2 171 65 Solna

+46 (0)8 730 37 00 info@xspraypharma.com

We use cookie to give you the best experience of our site. If you continue to use this website we will assume you agree. Read more about our Privacy policy.I agree